Celgene (CELG) Tops Q3 EPS by 2c; Guides In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cowen Reiterates Outperform on Celgene (CELG) Following a Soft 3Q
November 5, 2015 3:40 PM ESTCowen reiterated an Outperform rating and $150.00 price target on Celgene (NASDAQ: CELG), following the company's 3Q earnings report. Celgene reported non-GAAP EPS of $1.23, slightly beating consensus of $1.21. Revenues of $2.33B compared to consensus of $2.39B. TThe 18% growth in product sales was driven... More
Post-Q3 Selloff in Celgene (CELG) Probably Correction Following Recent Run - RBC
November 5, 2015 9:48 AM ESTRBC affirms Celgene Corp. (Nasdaq: CELG) at Outperform with a price target of $150 following Q3 results issued earlier.
Analyst Michael Yee noted that results for Celgene were relatively inline with expectations amid recently raised guiance when the company did its RCPT deal. The... More
